Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects.

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Benjamin BergerJasper Dingemanse

Abstract

Daridorexant (ACT-541468) is a new dual orexin receptor antagonist being evaluated for the treatment of insomnia, which is a common comorbidity of depression and anxiety. Therefore, daridorexant is likely to be administered concomitantly with agents (e.g., citalopram) used to treat these disorders. In this single-centre, single-blind, randomized, placebo-controlled, sequential design Phase 1 study with the inclusion of two double-blind crossover parts, the pharmacokinetic (PK; blood sampling at regular intervals) and pharmacodynamic (PD; battery of objective and subjective PD tests performed at regular intervals) interactions between daridorexant (50 mg) and citalopram (20 mg, single dose and at steady state) as well as the safety/tolerability in healthy subjects were investigated. There were no relevant effects of citalopram (single dose/steady state) on daridorexant exposure and vice versa. PD variables measured after morning administration of daridorexant alone showed effects consistent with a sleep-promoting compound. Only co-administration of daridorexant with citalopram at steady state led to relevant changes in objective (unstable tracking) and subjective (visual analogue scale alertness and Karolinska Sleepiness Scale) ...Continue Reading

References

May 1, 1990·The International Journal of Neuroscience·T Akerstedt, M Gillberg
Jan 1, 1981·Acta Pharmacologica Et Toxicologica·P Kragh-SørensenW Parnas
Mar 1, 1994·International Clinical Psychopharmacology·J Hyttel
Jan 1, 1993·European Archives of Psychiatry and Clinical Neuroscience·F HohagenM Berger
Jun 1, 1996·British Journal of Clinical Pharmacology·A L van SteveninckA F Cohen
Apr 30, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·O Spigset
Jan 5, 2002·The American Journal of Psychiatry·Andrew F LeuchterMichelle Abrams
Jun 14, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ian A CookSebastian H J Uijtdehaage
Aug 20, 2002·Psychopharmacology·Catherine J HarmerGuy M Goodwin
Dec 24, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C J HarmerG M Goodwin
Sep 17, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Bang-Ning YuHong-Hao Zhou
Jan 27, 2005·Journal of Psychopharmacology·Wim J RiedelJeroen A J Schmitt
Feb 12, 2005·The Journal of Clinical Psychiatry·Michael A Posternak, Mark Zimmerman
Apr 22, 2005·British Journal of Clinical Pharmacology·G J H DumontUNKNOWN Biomarker Working Group of the German Association for Applied Human Pharmacology
May 27, 2006·PLoS Medicine·Joanna Moncrieff, David Cohen
Jan 30, 2007·Journal of Psychopharmacology·M BrowningC J Harmer
Aug 30, 2008·The International Journal of Neuropsychopharmacology·Susannah E MurphyCatherine J Harmer
Nov 27, 2009·Sleep Medicine Reviews·Luc Staner
Jan 22, 2010·Nordic Journal of Psychiatry·Ulla Knorr, Lars Vedel Kessing
Feb 9, 2011·Journal of Affective Disorders·Chiara BaglioniDieter Riemann
May 7, 2011·Pharmacogenetics and Genomics·Katrin SangkuhlRuss B Altman
Jun 2, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Hans G CruzJasper Dingemanse
Dec 7, 2016·British Journal of Clinical Pharmacology·Xia ChenJoop van Gerven
Dec 18, 2016·Drug Discovery Today. Technologies·Geert Jan GroeneveldJohannes Marinus Van Gerven
Jul 1, 2017·The Journal of Pharmacology and Experimental Therapeutics·Alexander TreiberFrancois Jenck
Feb 16, 2018·Clinical Pharmacology and Therapeutics·Clemens MuehlanJasper Dingemanse
Oct 5, 2018·European Journal of Clinical Pharmacology·Marie-Laure BoofJasper Dingemanse
Jun 22, 2019·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Clemens MuehlanJasper Dingemanse

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.